EE177 Topical Sirolimus 0.2% Gel for Treatment of Facial Angiofibroma Associated with Tuberous Sclerosis Complex in the United States: A Budget Impact Analysis

Abstract

Facial angiofibroma (FA), one of the predominant dermatological manifestations of tuberous sclerosis complex (TSC) disorder, occurs in 75%-88% of patients. Managing FA with TSC adds a substantial clinical and economic burden on the healthcare system. We assessed the budget impact of including sirolimus 0.2% gel (HYFTOR™), the first and only US FDA approved topical medication for FA associated with TSC from a US third-party payer perspective (Commercial, Medicaid, and Medicare).